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Objectives. We studied the relations between heart failure, 
ejection fraction, arrhythmia suppression and mortality. 
Background. Both left ventricular ejection fraction and func- 
tional class of heart failure are strongly associated with mortality 
after acute myocardial infarction. Both are also related to the 
presence of ventricular arrhythmias and have been identified as 
factors related to the ability to suppress ventricular arrhythmias. 
Little has been reported about the relations between these two 
factors and arrhythmia suppression or mortality. 
Methods. Baseline data from the Cardiac Arrhythmia Suppres- 
sion Trial were used to define several categories of heart failure 
and to relate both the resulting categories and ejection fraction to 
arrhythmia suppression and mortality using logistic and survival 
regression analytic methodologies. 
Results. Regardless of the prospective baseline definition of 
heart failure used, the data consistently showed that heart failure 
was a more powerful predictor of subsequent congestive heart 
failure events and arrhythmia suppression and was equally pow- 
erful in predicting death. However, each variable provided incre- 
mental information when included in the prediction model. Heart 
failure and ejection fraction appeared to be independent predic- 
tors of death. Interactions were observed: A low ejection fraction 
was more predictive of failure of arrhythmia suppression in 
patients with than without evidence of heart failure before or at 
baseline; a low ejection fraction was more predictive of subsequent 
congestive heart failure events in patients without than with 
evidence of heart failure before or at baseline. 
Conclusions. Although heart failure as a prognostic feature 
appears to be somewhat superior to ejection fraction, both are 
powerful predictors of arrhythmia suppression and cardiac events 
in patients with ventricular arrhythmia after myocardial infarc- 
tion. Each provides incremental prediction. 
(J Am Coll Cardiol 1995;25:1250-7) 
Mortality after acute myocardial infarction is strongly associ- 
ated with extent of left ventricular dysfunction, judged either 
by quantitative means (left ventricular ejection fraction) or 
clinical assessment by functional class of heart failure (1-5). 
Previous studies (1,3) have identified ventricular arrhythmias 
as an independent predictor of sudden death and total cardio- 
vascular mortality after myocardial infarction. However, many 
relations exist between left ventricular function and spontane- 
ous ventricular arrhythmias. For example, the proportion of 
patients with nonsustained ventricular tachycardia ncreases as 
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left ventricular ejection fraction decreases or as heart failure 
status worsens (6,7). In the Cardiac Arrhythmia Suppression 
Trial (CAST) low arrfiytbmic death and total cardiac mortality 
rates were noted in patients with relatively preserved ejection 
fraction who were randomized to receive placebo (8). 
The CAST data base offers a rare opportunity to explore 
the relations between the clinical syndrome of congestive heart 
failure and ejection fraction. Both prognostic variables can be 
compared with subsequent clinical outcome and with the 
observed extent of arrhythmia suppression by CAST anti- 
arrhythmic drugs. Selected aspects of the open-label CAST 
experience, as well as the randomized placebo-controlled trial 
(main trial), have been reported that provide insights into 
these relations (8,9). The major goal of the present study was 
to analyze the relation between ejection fraction measured at 
baseline and baseline heart failure syndromes, defined by 
historic and baseline descriptors, with subsequent clinical 
outcomes in the patients enrolled in CAST. A second goal of 
this study was to evaluate the influence of baseline ejection 
fraction and heart failure syndromes on arrhythmia suppres- 
sion achieved uring the open-label phase. 
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Methods  
CAST study design. Details of the CAST study design have 
been described previously (8). Briefly, CAST included patients 
surviving acute myocardial infarction who had an average of 
->6 ventricular premature beats/h with at least 18 h of inter- 
pretable ambulatory electrocardiographic (ECG) recording, 
identified 6 days to 2 years after an acute myocardial infarc- 
tion. If the qualifying ambulatory ECG recording was obtained 
within 90 days of the myocardial infarction, an ejection fraction 
-<55% was required; >90 days after the index myocardial 
infarction, an EF of -<40% was required. Left ventricular 
ejection fraction was obtained from either routine angio- 
graphic, radionuclide or echocardiographic te hniques. Writ- 
ten informed consent was obtained before enrollment. 
There was a mandatory open-label phase in CAST that 
consisted of the unblindcd administration f encainide, flecain- 
ide or moricizine in specified sequences until a therapy was 
identified that achieved the CAST arrhythmia suppression 
goals (see definitions described later). The antiarrhythmic drug 
sequence was different for patients with ejection fraction 
<30% and those with ejection fraction ->30%; the former had 
an equal likelihood of the sequence ncainide-moricizine or 
moricizine-encainide, whereas the latter had equal ikelihood 
of either the sequence ncainide-moricizine-flecainide or 
flecainide-moricizine- encainide. 
Patient population. A total of 3,549 patients were enrolled 
in CAST (81% male, mean age 61.8 years, mean of 130 
ventricular premature beats/h). The mean duration of the 
open-label phase was 22 _+ 17 days. Over three fourths (76%) 
of enrollees achieved adequate arrhythmia suppression and 
were randomized to the successful antiarrhythmic therapy or 
matching placebo. Because the titration sequence was limited 
by the ejection fraction, the analysis relating ejection fraction 
and heart failure syndromes to suppression was restricted to 
patients randomized to encainide as the first drug in the 
titration sequence. This restriction provided an essentially 
random subset of 1,159 of the 3,549 patients enrolled, which 
did not confound the ejection fraction with the titration 
sequence but did restrict he analyses of suppression to the 
results with encainide. 
Description of ejection fraction measurement. Ejection 
fraction was measured in all patients in CAST, 42% by 
standard radionuclide techniques and the remainder by echo- 
cardiography orcontrast ventriculography. Preliminary explor- 
atory analysis indicated that the relation of ejection fraction to 
survival was quadratic rather than linear and was well de- 
scribed by dichotomizing ejection fraction at 30%. 
Definitions of congestive heart failure syndrome on the 
basis of baseline descriptors. Because it is not established 
which definition of heart failure is prognostically most useful, 
this study explored a range of three prospective definitions of 
a congestive heart failure syndrome. Definition 1 = a history of 
symptomatic congestive heart failure. There were 582 patients 
who met this definition enrolled in the open-label phase of 
CAST, of whom 187 were randomized to the encainide or 
flecainide limbs and 149 to the moricizine limb. Definition 2 = 
history of congestive heart failure as mentioned in definition 1
or physical examination evidence of congestive heart failure 
(tales, third heart sound [$3] gallop or jugular venous disten- 
tion) at the baseline xamination. This definition was met by 
783 patients enrolled in the open-label phase, of whom 240 
were randomized to the encainide or flecainide limbs and 214 
to the moricizine limb. Definition 3 = the broadest category, 
referred to as any congestive heart failure. It included the 
criteria of definition 2or the use of digitalis, diuretic agents or 
afterload reduction agents at the time of study entry. Decisions 
regarding these therapies were made solely by the individual 
physician, not mandated by protocol. Patients taking digitalis 
or diuretic agents for a supraventricular tachycardia, trial 
fibrillation or hypertension were not included. This third 
classification was met by 1,767 patients enrolled in the open- 
label phase of CAST, of whom 1,148 were randomized in the 
main trial (593 in the encainide/flecainide l mbs and 555 in the 
moricizine limb). 
The purpose of investigating a spectrum of prospective 
definitions of congestive heart failure was to determine the 
relative prognostic values of each. 
Definitions of end points in the main study. An events 
committee classified the following occurrences based on stan- 
dard prospective definitions developed inthe Cardiac Arrhyth- 
mia Pilot Study (10) using all available historic and clinical 
evidence, with blinding to the specific therapy. 
Death~cardiac rrest. Death or cardiac arrest was defined as 
spontaneous cessation of respiration and blood circulation 
(pulse) with loss of consciousness, whether or not resuscitation 
attempts were successful. This event occurred in 721 patients. 
Arrhythmic death~cardiac arrest. This event was defined 
prospectively asthe primary end point in the CAST study. It 
refers to witnessed, instantaneous death in the absence of 
severe congestive heart failure or cardiogenic shock; unwit- 
nessed eath with no preceding change in symptoms and for 
which no other cause could easily be ascribed, or cardiac arrest 
(without a nonarrhythmic cause) that resulted in resuscitation. 
This event occurred in 412 patients. 
Definite congestive heart failure. This event was defined as 
any death ascribed to congestive heart failure or hospitaliza- 
tion specifically for new or worsened congestive heart failure. 
It occurred in 328 patients (142 heart failure deaths, 186 
admitted to hospital). Note that this event was not recorded for 
patients after the open-label titration was completed if they 
were not randomized. 
An), evidence of congestive heart failure. This event included 
all patients with definite congestive heart failure or with 
development of new congestive heart failure, or worsening of 
congestive heart failure symptoms causing changes in heart 
failure therapy but not requiring hospital admission. It oc- 
curred in 690 patients. 
Definitions of arrhythmia suppression. In CAST, suppres- 
sion of ventricular premature beats required ->80% reduction 
compared with baseline; partial suppression referred to a 
degree of arrhythmia reduction (1% to 79%) falling short of 
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the study goal. For patients with ->10 runs of ventricular 
tachycardia, 90% suppression was required; for those with 1 to 
9 runs, total abolition of runs of ventricular tachycardia was 
required. 
Statistical methods. Baseline comparisons were by chi- 
square or t statistics where appropriate. Time to occurrence of 
death, cardiac arrest or development of heart failure was 
estimated by the method of Kaplan and Meier (11) and 
comparisons between groups were based on the log-rank 
statistic. Investigation of the relation of ejection fraction 
(<30% vs. ->30%), congestive heart failure syndrome and 
outcome was based on the proportional hazards regression 
model of Cox and was adjusted for the possible confounders of
age, previous myocardial infarction and diabetes (time from 
the index myocardial infarction to enrollment was not predic- 
tive, even univariately, inany of our models) (l 2). Because the 
outcome of definite congestive heart failure was not deter- 
mined for nonrandomized patients after completion of titra- 
tion, follow-up of these patients for this outcome was censored 
at completion of titration. Because of the design of CAST with 
an open-label titration before randomization, we could not 
adjust for assignment to active or placebo therapy. However, 
the adverse ffect of active therapy on death or on arrhythmic 
death was independent of ejection fraction and of a history of 
heart failure (13), so that active versus placebo therapy was not 
a confounder for the relative effects or interactions of these 
prognostic factors. The test of homogeneity of common odds 
or relative risks was based on the method of Cornfield (14). 
Analysis of the relation of baseline ejection fraction and 
heart failure status to arrhythmia suppression during the 
open-label titration was performed using multivariate logistic 
regression (15), conditioning for age and history of myocardial 
infarction. Other factors such as gender, time from the myo- 
cardial infarction to titration and a history of diabetes had not 
been associated univariately with suppression. 
Resu l ts  
Relation of heart failure, ejection fraction and arrhythmia 
suppression. The overall results of titration and the risk 
profiles of those not receiving suppression and not randomized 
to long-term therapy are reported elsewhere (16). Patients 
whose arrhythmias were not suppressed had lower ejection 
fractions, more frequently had a history of congestive heart 
failure and a greater use of digitalis and diuretic agents and 
had a lower mean frequency of ventricular premature beats 
(16). 
To examine the relation of baseline heart failure status and 
ejection fraction to the extent of ventricular arrhythmia sup- 
pression achieved, we evaluated an unbiased sample of 1,159 
patients first tested for ventricular arrhythmia suppression on 
encainide (patients who started titration on encainide were a 
randomly selected subsample of all the enrolled patients). 
These 1,159 patients included 16% with a history of heart 
failure (definition 1). The comparative frequency of ventricular 
premature beats in patients with and without a history of heart 
failure was 141 _+ 243/h versus 126 + 250/h (p NS). Patients 
with a history of heart failure had more frequent runs of 
nonsustained ventricular tachycardia (30% vs. 21%; p < 0.01). 
Patients with a history of heart failure were less likely to 
achieve the arrhythmia suppression criteria required by CAST 
than were those without heart failure (58% vs. 75%; p < 
0.001). The results were similar for heart failure definitions 2
and 3. Left ventricular ejection fraction obtained at baseline 
also was significantly related to suppressibility; 75% of patients 
with ejection fraction ->30% at baseline had their arrhythmias 
suppressed, compared with 64% of patients whose ejection 
fraction was <30% (p < 0.001). 
We performed an analysis to determine the relative contri- 
bution of baseline heart failure status and ejection fraction 
(<30% vs. ->30%) to the degree of observed arrhythmia 
suppression. By univariate stepwise logistic regression, both a 
history of congestive heart failure (p < 0.0007 for any of the 
three definitions) and a lower ejection fraction (p = 0.0015) 
were associated with the failure to achieve arrhythmia suppres- 
sion. A history of heart failure remained strongly predictive 
after adjusting for ejection fraction, age and history of myo- 
cardial infarction (p < 0.009). Left ventricular ejection fraction 
was marginally predictive after adjusting for any of the three 
definitions of heart failure, age and history of myocardial 
infarction (p < 0.03). A marginally significant interaction was 
observed between ejection fraction and heart failure (defini- 
tion 1, p = 0.06; definition 2, p = 0.08; definition 3, p = 0.47): 
In patients without evidence of heart failure before or at 
baseline, the risk of failure to achieve arrhythmia suppression 
associated with lower versus higher ejection fraction was about 
half that for patients with a heart failure syndrome. Figure 1 
illustrates the proportion of patients achieving arrhythmia 
suppression i this sample of the 1,159 patients first treated for 
suppression with encainide. The figures characterize the re- 
sponse by the three definitions of heart failure and subcatego- 
rized by high versus low ejection fraction. 
Influence of ejection fraction on clinical outcome. Left 
ventricular ejection fraction was strongly related to each of the 
four major prospectively defined clinical outcome variables of 
CAST, as shown in Table 1. Patients with ejection fraction 
<20% had a 75% major clinical event rate (death, cardiac 
arrest, congestive heart failure) during the 23-month mean 
follow-up period in the CAST; in contrast, only 22% of the 416 
patients with ejection fraction ->50% had major clinical events 
(p < 0.0001). 
Clinical value of baseline heart failure status. Patients 
meeting any of the three definitions of congestive heart failure 
syndrome at baseline generally had a twofold higher mortality 
rate and a threefold increase in congestive heart failure events 
(Table 2) compared with those not meeting the definition. 
The incidence of clinical congestive heart failure requiring 
hospital admission or leading to death in the active and 
placebo treatment groups was recorded, stratified for baseline 
ejection fraction (Table 1, brackets) and baseline heart failure 
classifications (Table 2, brackets). The results demonstrate the 
underreporting expected because hospital admission for heart 
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Figure 1. Top, Relation of left ventricular ejection frac- 
tion (EF) to (top) history of congestive heart failure 
(CHF); (middle) congestive heart failure by history or 
examination; and (bottom) any indicator of congestive 
heart failure in predicting arrhythmia suppression. Per- 
cents refer to patients achieving CAST arrhythmia sup- 
pression criteria. See Methods for definitions of conges- 
tive heart failure. 
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failure after completion of titration was not recorded for those 
patients not randomized. For reference the incidence of any 
heart failure event is also shown in brackets for the random- 
ized patients. For all congestive heart failure events the 
randomized patients had an incidence of 14.5% compared with 
19% for all enrolled patients. For definite (requiring hospital 
admission or leading to death) heart failure events the corre- 
sponding incidences were 9.5% and 9%, respectively. This 
suggests underreporting of 2% to 3%. Although there was a 
greater incidence of definite heart failure events occurring in 
the stratum with ejection fraction <20%, this finding did not 
reach statistical significance. 
Table 1. Clinical Outcome Stratified by Left Ventricular Ejection Fraction at Baseline in the Cardiac Arrhythmia Suppression Trial 
No. of Death~Cardiac Arrhythmic Death,'* Definite CHF 
LVEF (%) Pts Arrest Cardiac Arrest Events All CHF Events 
<20 190 48% 27r;~ 22% [44%:13%J* 40% [52%:19%]* 
20-29 797 30% 18% 15% [17%:20%] 30% [24%:26%] 
30 39 1,318 17% 10% 8% [9%:8%] 19% [15%:15%] 
40-49 828 14% 7~:~ 5% [5%:6%] 12% ]9%:9%] 
->50 416 13c;,'~ 6% 3% [3%:1%] 7% [7%:3%] 
Total 3,549 20% 12% 9% [10%:9%] 19% [16%:13%] 
*Restricted to the 1,257 patients (Pts) randomized to receive active therapy and the 1,234 patients randomized to receive placebo therapy [active:placebo]. 
CHE = congestive heart failure; LVEF = left vcntricular ejection fraction. 
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Table 2. Clinical Outcome Stratified by Heart Failure Status at Baseline in the Cardiac Arrhythmia Suppression Trial 
No. of Death/Cardiac Arrhythmic Death/ Definite CHF 
Pts Arrest Cardiac Arrest Events All CHF Events 
History of CHF 
Yes 582 40% 24% 21% [25%:26%]* 39% [35%:35%]* 
No 2.967 17% 9% 7% [8%:7%] 16% [12%:8%] 
Histo H of CHF + physical exam 
evidence of CHF 
Yes 783 38f,i 22% 20% [24%:24%] 38% [33%:35%] 
No 2,7(~(~ 15% 9% 6% I7%:6%1 14% [13%:9%] 
History of CHF ~- physical exam 
evidence of CHF + 
medications for CHF 
Yes 1.767 28% 16% 15% [18%:17%] 30% [26%:22%] 
No 1,782 13% 7% 4% [3%:4%] 9% [6%:6%] 
*Restricted to the 1,257 patients randomized toreceive active therapy and the 1,234 patients randomized toreceive placebo therapy [active:placebo]. Abbreviations 
as in Table 1. 
Do baseline jection fraction and heart failure assessments 
provide complementary prognostic information? The contri- 
butions of the baseline jection fraction and baseline conges- 
tive heart failure syndromes in predicting survival were inves- 
tigated using regression analysis and are depicted in Figure 2. 
Ejection fraction and congestive heart failure status were 
equally and independently predictive of survival (for each 
factor, p < 0.001 after adjustment for age, history of myocar- 
dial infarction, history of diabetes and the other factor). The 
survival data presented in Figure 2 are for total mortality/ 
cardiac arrest, and the relation for the end point of arrhythmic 
death were identical. 
Figure 3 presents the relation of heart failure syndromes 
obtained at entry and baseline jection fraction assessments in 
predicting subsequent heart failure hospital admissions or 
death due to heart failure for each of the three prospective 
definitions of heart failure syndrome. Consistent with the 
observations from the analyses in Figures 1 and 2, each of the 
three syndromes of congestive heart failure at baseline and 
lower ejection fraction significantly (p < 0.0001 after adjust- 
ment for age, history, diabetes and gender) identified patients 
who were likely to require rcadmission to hospital for new or 
worsened congestive heart failure. No single definition ap- 
peared superior. Ejection fraction provided significant addi- 
tional discrimination after adjustment for any of the three 
heart failure indexes, and each of the three heart failure 
indexes provided significant additional discrimination after 
adjusting for ejection fraction (all comparisons p < 0.0004). 
There was a significant interaction of ejection fraction and 
heart failure status per definitions 1 and 2 but not definition 3 
(definition 1, p = 0.001; definition 2, p = 0.005; definition 3, 
p = 0.54): the relative risk associated with heart failure per 
definition 1 was 1.9 in patients with low ejection fraction and 
4.0 in patients with high ejection fraction; per definition 2 it 
was 1.9 and 3.8, respectively. 
Discuss ion  
The CAST study provides a large data base to explore the 
relation between clinical congestive heart failure, ejection 
fraction and arrhythmia suppression. Of the 3,549 patients with 
ventricular arrhythmias surviving acute myocardial infarction 
and tested with antiarrhythmic therapy, -76% achieved ar- 
rhythmia suppression by CAST criteria. The presence or 
absence of congestive heart failure before or at baseline was 
prognostically important; only 58% of patients with a history of 
heart failure achieved arrhythmia suppression compared with 
75% of patients without such a history. Regardless of which 
prospective definition of heart failure was used, ejection 
fraction made an important contribution i predicting arrhyth- 
mia suppression, particularly in patients with no history of and 
no heart failure at baseline. In the highest risk CAST popula- 
tion (with both congestive heart failure syndrome and ejection 
fraction <30%), nearly 50% did not achieve arrhythmia sup- 
pression. Thus, there is a significant loss of drug effect in the 
subset of the CAST population known to be at higher isk for 
arrhythmic death. 
Both heart failure status and ejection fraction provided 
incremental prediction of ventricular arrhythmia suppression. 
Our data suggest that baseline heart failure status is a more 
significant predictor than ejection fraction as measured in 
CAST. 
The information on the relation of heart failure status tc 
arrhythmia suppression i a population with mild to moderate 
left ventricular dysfunction is complementary to previous. 
published observations on the relation of ejection fraction to 
arrhythmia suppression. In a report of 201 patients with lethal 
ventricular arrhythmias, antiarrhythmic drugs more commonly 
failed to prevent inducible sustained ventricular tachycardia 
when the ejection fraction was <40% (17). Likewise, a Holter 
analysis of arrhythmia suppression in 246 patients with fre.. 
quent ventricular premature beats revealed a significantly, 
poorer arrhythmia suppression rate in patients with ejection 
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fraction (EF) to (top) history of congestive heart failure 
(CHF); (middle) congestive heart failure by history or 
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fraction <40% (18). In addition, a sevenfold increase in 
life-threatening complications due to antiarrhythmic drugs 
occurred in the 61 patients with a baseline ejection fraction 
<30% (18). 
During the open-label titration in this study, we observed 
event rates (death, cardiac arrest and all heart failure events) 
as high as 13% to as low as 3% for ejection fraction strata of 
<20% and >50%, respectively. This consistent relation be- 
tween ejection fraction and antiarrhythmic drug efficacy or 
toxicity highlights the serious limitations of currently available 
antiarrhythmic drugs (17-19). These results also emphasize the 
difficulty in testing the hypothesis that suppressing these arrhyth- 
mias would improve prognosis: unfortunately, the patients most 
likely to benefit from antiarrhythmic therapy (by showing a 
reduction in mortality) have the least likelihood of achieving 
arrhythmia suppression, but a higher potential for toxicity. 
The evaluation of the relation between heart failure status, 
ejection fraction and arrhythmia suppression was performed 
on patients randomly selected to receive encainide as the first 
drug, sometimes followed by moricizine. For this particular 
analysis, flecainide patients were not used because they would 
have biased our goal of exploring relations between ejection 
fraction and suppression. Patients with baseline jection frac- 
tions <30% could not receive flecainide based on observations 
of new or worsened heart failure in patients treated with 
flecainide in the Cardiac Arrhythmia Pilot Study (CAPS) (20). 
However, we performed an identical analysis of all open-label 
patients, the results of which are totally consistent with the 
analyses presented. 
Assessment of heart failure status at baseline: a simple, 
important prognostic variable. The CAST data base allowed 
testing of the prognostic ontributions of a number of prospec- 
tive definitions of congestive heart failure in a postinfarction 
population ot selected for significant left ventricular dysfunc- 
tion, thus consisting primarily of patients with minimal or 
modest left ventricular dysfunction. A history of heart failure 
alone or combined with physical examination evidence of heart 
failure at the time of randomization was equally powerful, 
identifying a patient population with a twofold increased risk 
of death. 
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Figure 3. Relative contribution f left ventricular ejec- 
tion fraction (EF) to (top) history of congestive h art 
failure (CHF); (middle) congestive heart failure by 
history or physical examination; and (bottom) any 
indicator of congestive heart failure in predicting 
definite congestive h art failure vents. Each number 
in box refers to survival free of heart failure vents. 
Previous reports have focused on patients with overt con- 
gestive heart failure. For example, Wilson et al. (21) studied 77 
patients and noted a 6.8-fold increase in deaths at 1 year in 
patients with class IV rather than class III symptoms at 
baseline. This and other studies are small in comparison to the 
present report and focused on symptomatic or hospitalized 
patients with heart failure. What is striking in the present study 
is the prognostic benefit of assessing baseline congestive heart 
failure status in a large, predominantly asymptomatic popula- 
tion. 
Relative importance of heart failure status and ejection 
fraction in predicting cardiac events after myocardial infarc- 
tion. Previous tudies have established that ejection fraction is 
a powerful predictor of clinical outcome (1-5). Our results are 
in complete agreement. 
Because both heart failure status and measurement of left 
ventricular ejection fraction were analyzed prospectively in all 
CAST patients at baseline, we were interested in the relative 
contributions of both expressions of left ventricular dysfunc- 
tion in assessing prognosis. Regardless of the prospective 
baseline definition of heart failure used, the data consistently 
show that heart failure as a determinant of subsequent death is 
as important as ejection fraction. Moreover, they appear to be 
independent predictors of death. However, heart failure status 
appears to be more predictive of subsequent congestive heart 
failure events with the relative risk dependent on ejection 
fraction. A history of heart failure identified a population at 
four times increased risk for significant congestive heart failure 
requiring hospitalization or causing death among those with 
preserved left ventricular function. The increased risk was 
twofold among those with ejection fraction -<30%. The broad- 
est definition of congestive heart failure appeared less useful in 
discriminating the high-risk population. 
Previous studies addressing this issue focused on patients 
with symptomatic heart failure. In assessing the relative con- 
tributions of heart failure and ejection fraction, Glover and 
Littler (22) reported on 50 patients with heart failure second- 
ary to ischemic ardiomyopathy. In that study, ejection frac- 
tion, $3 gallop, class IV heart failure symptoms and severe 
ventricular arrhythmia predicted outcome. However, class FV 
heart failure status predicted early mortality whereas ejection 
fraction was more useful in predicting long-term prognosis 
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Measurements of left ventricular systolic performance such as 
ejection fraction do not necessarily correlate with the symp- 
tomatic status of patients with heart failure (23). In a report of 
236 patients with a history of congestive heart failure, Califf et 
al. (24) found the following to be independent predictors of 
survival: class IV heart failure, left main coronary artery 
stenosis, decreased ejection fraction and widened arterio- 
venous oxygen difference. Cohn et al. (25) believed that 
exercise tolerance and left ventricular function contributed 
independently o prognosis. The present report extends these 
previous observations to an ambulatory patient population 
with more subtle or frequently asymptomatic left ventricular 
dysfunction. 
Conclusions. The CAST study provides a substantial data 
base from which to make observations on the degree to which 
heart failure status and ejection fraction contribute to predict- 
ing clinical outcome and arrhythmia suppression. Although 
both variables are predictive, heart failure status appears 
somewhat superior in predicting heart failure events and 
arrythmia suppression and equally predictive of death. The 
predictive ffects of ejection fraction and baseline heart failure 
status were largely independent of each other although there 
was some interaction. The absence of heart failure at baseline 
had a strong relation to arrhythmia suppression and predicted 
a lower mortality. 
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